Australian CAR-T trials – Car-T Central

CARTITUDE-4 trial: Cilta-cel vs standard of care in lenalidomide-refractory multiple myeloma patients

CARTITUDE-4 is a randomised, phase III study comparing the efficacy and safety of cilta-cel vs SOC in lenalidomide-refractory patients treated with 1-3 prior LOT.

ZUMA-23: A first-line CAR-T trial in LBCL, presented at ASCO 2023

The Phase 3 ZUMA-23 trial will evaluate the efficacy of axi-cel as a first-line treatment for LBCL patients. This study is currently enrolling at Australian sites.